Genprex Inc., of Austin, Texas, said it entered into purchase agreements with institutional investors for a private placement of $10 million of shares of its common stock and warrants. The price of the common stock is $12.07 each, and the initial exercise price for the warrants is equal to $15.62 per share. The company's gene therapy platform includes product candidate, Oncoprex immunogene therapy for non-small-cell lung cancer.